MIRAPEX ER
PeakNDAORALTABLET, EXTENDED RELEASE
Approved
Feb 2010
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRAPEX ER is an extended-release oral tablet formulation of pramipexole, a dopamine agonist approved in 2010. The drug's mechanism of action and specific indications are not detailed in available data, but dopamine agonists are typically used for movement disorders and restless leg syndrome. Patient eligibility and therapeutic context depend on the primary indication.
Peak3.3 years to LOE
At peak lifecycle with 3.4 years of patent exclusivity remaining; brand teams should expect resource optimization and defensive positioning against upcoming generic entry.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Worked on MIRAPEX ER at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.